Vaginitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Feb. 9, 2012 - PRLog -- GlobalData has estimated that the global vaginitis therapeutics market was valued at $453.1m in 2006, before increasing at a Compound Annual Growth Rate (CAGR) of 2.43% to reach $510.9m in 2011. The market is expected to increase to $620.5m by 2019, at a CAGR of 2.46%. The current market is flooded with drugs which are used both on-label and off-label, but an increase in the incidence of vaginitis cases, caused by a rise in general population, will account for this slight growth during the forecast period. Overthe- Counter (OTC) drugs are also present in the market, due to which self-treatment is prevalent. The products in the market can be broadly classified as anti-protozoals, anti-fungals and lincosamides. Antiprotozoals are generic, such as metronidazole and Tindamax (tinidazole). In the US, Tindamax (tinidazole, 250mg and 500mg oral tablets), of Mission Pharmacal, was approved in 2004 for trichomoniasis and 2007 for Bacterial Vaginitis (BV). Pfizer has marketed 500mg oral tablets of tinidazole in Europe (under the trade name Fasigyn) since receiving approval in 1994. Metronidazole is the standard choice of treatment for BV and trichomoniasis; however, tinidazole is the first new oral therapy to be approved by the FDA for the treatment of BV and trichomoniasis. Itraconazole, ketoconazole, fluconazole, miconazole, clotrimazole, butoconazole and nystatin are included under anti-fungals for the treatment of vaginal candidiasis. In the lincosamide class, clindamycin phosphate vaginal cream is used for the treatment of BV. These drugs are currently effective in the treatment of vaginitis, and all are generics.

Competition in the vaginitis therapeutics market is strong, according to GlobalData’s assessment. The market is populated by generics and many off-label drugs for the treatment of vaginitis. The current treatment options are indicated for the relief of symptoms in symptomatic infections, and for the prevention of postoperative infections in those with asymptomatic infections. The current treatment options have good efficacy and safety profiles. The market has various treatment options which are successful in meeting the market demand, but scope still exists for new entrants into the market. The current players will remain as the market leaders for at least the next seven years, as the pipeline has no first-in-class drugs that could further intensify competition in the near future.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


GlobalData’s analysis suggests that there is a low unmet need in the vaginitis therapeutics market, and the market is currently well-served by a number of treatment options. There are a number of potent antifungal agents such as metronidazole and tinidazole available in the market. They can be used either systemically or topically depending upon the type of vaginitis and its severity. These azole antifungals are available both Over-the-Counter (OTC) or by prescription, which suggests that the therapeutic needs for vaginitis infection are low. However, unmet needs still exists in the vaginitis therapeutics market with respect to the unavailability of treatment options that address all three types of microorganism (bacteria, fungi, protozoa) that cause vaginitis. Increased attention needs to be paid to the treatment of recurrent vaginitis with improved dosage regimens and alternatives to azole therapy for azole-resistant candidiasis. There is also a need to develop some novel diagnostic method with greater sensitivity

GlobalData, the industry analysis specialist, has released its new report, “Vaginitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global vaginitis therapeutics market, and identifies the key trends shaping and driving the global vaginitis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global vaginitis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Vagi...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.